At the heart of the Dutch court case on Humira is the question of whether there ought to be limits to what a company can ...

Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill. Here's why they think ...

The US company had pinned its hopes on the Ablynx drug being a strong successor to Humira, but AbbVie got spooked by data from a second phase 2b trial. The results showed vobarilizumab missed its ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations ...

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

In his 35 years with AbbVie, Salfeld has been personally involved in growing a small startup in a leased space in Cambridge into a biopharmaceutical powerhouse.

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

AbbVie - for the first decade after its spin-out from Abbott Laboratories (ABT) in 2012 - was synonymous with its best-selling drug Humira, the tumor necrosis factor-alpha inhibitor indicated for ...